MedTrace Logo

Evaluation of a New Sequencing Strategy in Autoinflammatory Siseases (BIOSAID)

NCT02976948 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 299

Last updated 2021-12-30

No results posted yet for this study

Summary

Main objective: To compare the efficacy of a new strategy of Next Generation Sequencing (NGS) versus a classical Sanger strategy, for the diagnosis of patients referred to the laboratory for suspected systemic autoinflammatory diseases (SAID).

Secondary objectives:

* Compare after 6 months the impact of these strategies on the establishment of an effective treatment SAID following genetic result.
* Compare the distribution of different forms of SAID found with each genetic diagnostic strategies (NGS vs classic method).

Conditions

  • Systemic Autoinflammatory Diseases (SAID)

Interventions

OTHER

No intervention

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Guillaume SARRABAY, md · University Hospital, Montpellier

Eligibility

Min Age
3 Months
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-07-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02976948 on ClinicalTrials.gov